Correlation Between Alnylam Pharmaceuticals and Viking Therapeutics
Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Viking Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Viking Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alnylam Pharmaceuticals and Viking Therapeutics, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Viking Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Viking Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Viking Therapeutics.
Diversification Opportunities for Alnylam Pharmaceuticals and Viking Therapeutics
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Alnylam and Viking is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Viking Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viking Therapeutics and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Viking Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viking Therapeutics has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Viking Therapeutics go up and down completely randomly.
Pair Corralation between Alnylam Pharmaceuticals and Viking Therapeutics
Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to under-perform the Viking Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Alnylam Pharmaceuticals is 2.24 times less risky than Viking Therapeutics. The stock trades about -0.25 of its potential returns per unit of risk. The Viking Therapeutics is currently generating about -0.07 of returns per unit of risk over similar time horizon. If you would invest 6,039 in Viking Therapeutics on August 24, 2024 and sell it today you would lose (876.00) from holding Viking Therapeutics or give up 14.51% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Alnylam Pharmaceuticals vs. Viking Therapeutics
Performance |
| Timeline |
| Alnylam Pharmaceuticals |
| Viking Therapeutics |
Alnylam Pharmaceuticals and Viking Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Alnylam Pharmaceuticals and Viking Therapeutics
The main advantage of trading using opposite Alnylam Pharmaceuticals and Viking Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Viking Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viking Therapeutics will offset losses from the drop in Viking Therapeutics' long position.| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
| Viking Therapeutics vs. Terns Pharmaceuticals | Viking Therapeutics vs. Akero Therapeutics | Viking Therapeutics vs. Madrigal Pharmaceuticals | Viking Therapeutics vs. Sarepta Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |